BioLife Solutions (BLFS) AI Stock Analysis

• Market Cap: $1.34B
• Dividend Yield: N/A
• Average Volume (3M): 364.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.86
• Revenue Growth: -18.61%
• EPS Growth: 92.36%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.33
• Shares Outstanding: 47,905,266
• 10 Day Avg. Volume: 286,679
• 30 Day Avg. Volume: 364,263
• PEG Ratio: 0.83
• Price to Book (P/B): 3.43
• Price to Sales (P/S): 14.54
• P/FCF Ratio: 229.80
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 12.70
• Enterprise Value/Gross Profit: 15.60
• Enterprise Value/Ebitda: -148.02
• 1Y Price Target: $31.38
• Price Target Upside: 16.65% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 60 Neutral
• Price Target: $29.00 ▲(7.81% Upside)

BioLife Solutions' overall stock score is driven by strong earnings call results and positive technical indicators, suggesting potential for growth. However, financial performance issues, particularly profitability and valuation concerns, weigh down the score. The company's strategic investments and revenue growth provide optimism, but operational efficiency improvements are necessary for a stronger financial position.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong demand for BioLife's products, suggesting a robust market position and potential for sustained expansion in the cell and gene therapy sectors.

Strategic Investment

Investing in Pluristyx enhances BioLife's product offerings and market reach, supporting long-term growth by leveraging innovative iPSC-based products in the biopreservation market.

Strong Balance Sheet

A strong balance sheet with low leverage provides financial stability and flexibility, enabling BioLife to invest in growth opportunities and withstand market fluctuations.

Negative Factors

Decreased Gross Margin

A declining gross margin indicates potential cost management issues, which could impact profitability if not addressed, affecting long-term financial health.

Increased Operating Expenses

Rising operating expenses, particularly from noncash IPR&D, may strain profitability and require efficiency improvements to maintain financial performance.

Negative Profit Margins

Ongoing negative profit margins highlight challenges in achieving profitability, necessitating operational improvements to enhance long-term financial viability.

BioLife Solutions Business Overview & Revenue Model

Company Description

BioLife Solutions (BLFS) is a leading provider of proprietary biopreservation tools and services for the cell and gene therapy sectors. The company specializes in the development and production of biopreservation media, cryopreservation solutions, and storage systems that ensure the viability and functionality of biologic materials during storage and transportation. Its core products include CryoStor, HypoThermosol, and other proprietary solutions designed to optimize the preservation of cellular therapies, tissue, and organs for transplantation.

How the Company Makes Money

BioLife Solutions generates revenue primarily through the sale of its biopreservation products and services to a diverse range of customers, including pharmaceutical companies, research institutions, and clinical laboratories involved in cell and gene therapy. Key revenue streams include direct sales of its proprietary media and cryopreservation solutions, as well as recurring revenue from long-term contracts with customers for product supply. The company also benefits from strategic partnerships with biotech firms and research organizations that enhance its market reach and product development capabilities. Additionally, BioLife Solutions may see increased earnings through collaborations that expand its product offerings and enter new markets, capitalizing on the growing demand for biopreservation solutions in the rapidly evolving life sciences sector.

BioLife Solutions Financial Statement Overview

Summary

BioLife Solutions faces challenges with declining revenues and profitability, as reflected in its income statement. Despite a strong balance sheet with low leverage, the negative return on equity highlights the need for improved profitability. Cash flow generation is improving, but alignment with earnings needs attention. Overall, the company should focus on enhancing operational efficiency and profitability to strengthen its financial position.

Income Statement

BioLife Solutions has experienced declining revenues over the past periods, with a TTM revenue decrease of 3.66%. The gross profit margin is strong at 82.67% TTM, indicating efficient cost management. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The net profit margin is -7.23% TTM, showing significant losses. The company needs to address its operational inefficiencies to improve profitability.

Balance Sheet

The balance sheet shows a stable financial position with a low debt-to-equity ratio of 0.069 TTM, indicating conservative leverage. The equity ratio is healthy, suggesting a strong capital structure. However, the return on equity is negative at -1.61% TTM, reflecting ongoing losses. The company should focus on improving its return on equity by enhancing profitability.

Cash Flow

Cash flow analysis reveals positive operating cash flow of $15.54 million TTM, which is a positive sign. The free cash flow has grown significantly, indicating improved cash generation. However, the operating cash flow to net income ratio is 0.55, suggesting that cash flow generation is not fully aligned with earnings. The company should aim to convert more of its earnings into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	76.51M	82.25M	143.27M	76.24M	119.16M	48.09M
Gross Profit	62.30M	53.67M	46.75M	53.82M	37.75M	27.44M
EBITDA	-6.56M	1.53M	-45.24M	-124.18M	-16.65M	1.48M
Net Income	-5.53M	-20.18M	-66.43M	-139.81M	-8.91M	2.67M
Balance Sheet
Total Assets	387.24M	399.49M	412.71M	450.23M	552.60M	234.83M
Cash, Cash Equivalents and Short-Term Investments	81.77M	104.58M	51.70M	62.70M	69.87M	90.46M
Total Debt	23.82M	30.17M	42.69M	43.71M	26.88M	11.15M
Total Liabilities	40.09M	50.58M	75.05M	86.04M	71.85M	29.58M
Stockholders Equity	347.15M	348.91M	337.66M	364.19M	480.75M	205.25M
Cash Flow
Free Cash Flow	11.45M	5.20M	-18.88M	-18.87M	-13.22M	1.88M
Operating Cash Flow	15.54M	8.43M	-12.50M	-8.49M	-4.84M	6.51M
Investing Cash Flow	5.25M	58.30M	17.84M	-58.12M	-12.64M	-23.73M
Financing Cash Flow	-11.00M	-6.78M	10.59M	16.32M	-2.78M	102.08M

BioLife Solutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Positive. The current price of 26.9 is below the 20-day moving average (MA) of 27.61, above the 50-day MA of 26.39, and above the 200-day MA of 24.43, indicating a bullish trend. The MACD of 0.48 indicates Positive momentum. The RSI at 55.22 is Neutral, neither overbought nor oversold. The STOCH value of 26.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLFS.

BioLife Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLFS	―	$1.34B	-235.39	-5.98%	―	-18.61%	92.36%
KMTS	―	$1.44B	―	―	―	83.78%	-25.37%
AZTA	―	$1.38B	-12.41	-1.74%	―	-8.15%	13.50%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SMTI	―	$256.48M	―	-25.78%	―	34.29%	-49.21%
STAA	―	$1.28B	-13.39	-25.55%	―	-32.59%	-667.81%
PLSE	―	$1.14B	-16.05	-103.50%	―	―	-33.24%

BioLife Solutions Corporate Events

BioLife Solutions Holds Annual Stockholders Meeting

On August 20, 2025, BioLife Solutions, Inc. conducted its annual meeting of stockholders, where key decisions were made. The stockholders re-elected seven directors, approved executive compensation on a non-binding basis, and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (BLFS) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on BioLife Solutions stock, see the BLFS Stock Forecast page.

BioLife Solutions Reports Strong Q2 Growth Amid Challenges

BioLife Solutions Inc. recently held its Q2 2025 earnings call, showcasing a mixed sentiment among stakeholders. The company reported significant revenue growth and increased guidance, reflecting strong operational performance and future potential. However, the overall financial results were tempered by increased operating expenses and net loss, primarily due to noncash charges. Despite these challenges, BioLife’s robust cash position and strategic investments suggest a promising outlook for future growth.

BioLife Solutions Reports Strong Q2 2025 Growth

BioLife Solutions Inc., a prominent player in the cell and gene therapy market, specializes in developing and supplying cell processing tools and services. The company is recognized for its biopreservation media and other innovative solutions that support the commercialization of new therapies.